In the hyperglycaemic clamp setting, olanzapine impaired beta‐cell insulin secretion.(11) Two‐week subchronic olanzapine treatment induced dyslipidaemia in rats despite no excess weight gain. This evidence concerns the gene INS and inherited lipid metabolism disorder.